02012nas a2200445   4500000000100000008004100001260001600042653001000058653000900068653001700077653002500094653003700119653001400156653001100170653004100181653001100222653003000233653002100263653002500284653002800309653000900337653001600346653002200362653002500384100001300409700001400422700001300436700001200449700001500461700001200476700001500488700001400503700001600517700001400533245015400547300001200701490000800713520083100721022001401552       1990                            d  c1990 Nov 0110aAdult10aAged10aAntigens, CD10aBacterial Infections10aDose-Response Relationship, Drug10aEpidermis10aFemale10aHistocompatibility Antigens Class II10aHumans10aInjections, Intramuscular10aInterferon-gamma10aLeprosy, lepromatous10aLeukocytes, Mononuclear10aMale10aMiddle Aged10aNeurons, Afferent10aRecombinant Proteins1 aNathan C1 aSquires K1 aGriffo W1 aLevis W1 aVarghese M1 aJob C K1 aNusrat A R1 aSherwin S1 aRappoport S1 aSanchez E00aWidespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma.  a1509-120 v1723 a<p>Intradermal administration of recombinant interferon gamma (rIFN-gamma) to lepromatous leprosy patients has converted the local histology toward a tuberculoid pattern. However, such changes have been confined to the site of injection. In contrast, in the present study, marked, intradermal accumulation of CD3+, CD4+, CD8+, and CD1a+ T cells and Leu-M5+ mononuclear phagocytes was induced at a distance from the sites of administration, in a dose-dependent manner, by 10 daily intramuscular injections of 10-30 micrograms rIFN-gamma/m2. Mononuclear cell infiltration began within 3 d of onset of rIFN-gamma therapy and persisted at least 8 wk. Intramuscular administration of rIFN-gamma to lepromatous patients receiving concurrent chemotherapy can safely induce widespread histologic features of an upgrading reaction.</p>  a0022-1007